SOFIVA GENOMICS Co (ROCO:6615) Cyclically Adjusted Revenue per Share: NT$26.70 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6615 SOFIVA GENOMICS Co Ltd ROCO:6615
68 GF Score
Price NT$34.00
GF Value NT$31.65
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is SOFIVA GENOMICS Co Cyclically Adjusted Revenue per Share?

SOFIVA GENOMICS Co ROCO:6615 -1.02% 68 Cyclically Adjusted Revenue per Share is NT$26.70 as of Mar. 2026. GuruFocus rates ROCO:6615 with a GF Score™ of 68/100 and a GF Value™ of NT$31.65 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

SOFIVA GENOMICS Co's adjusted revenue per share for the three months ended in Mar. 2026 was NT$4.297. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$26.70 for the trailing ten years ended in Mar. 2026.

During the past 12 months, SOFIVA GENOMICS Co's average Cyclically Adjusted Revenue Growth Rate was -1.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-13), SOFIVA GENOMICS Co's current stock price is NT$34.00. SOFIVA GENOMICS Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was NT$26.70. SOFIVA GENOMICS Co's Cyclically Adjusted PS Ratio of today is 1.27.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of SOFIVA GENOMICS Co was 1.41. The lowest was 1.09. And the median was 1.23.


SOFIVA GENOMICS Co  (ROCO:6615) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

SOFIVA GENOMICS Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=34.00/26.70
=1.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of SOFIVA GENOMICS Co was 1.41. The lowest was 1.09. And the median was 1.23.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


SOFIVA GENOMICS Co Cyclically Adjusted Revenue per Share Related Terms


SOFIVA GENOMICS Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for SOFIVA GENOMICS Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SOFIVA GENOMICS Co Cyclically Adjusted Revenue per Share Chart

SOFIVA GENOMICS Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 26.69

SOFIVA GENOMICS Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.05 27.08 26.98 26.69 26.70

ROCO:6615 vs TMO, DHR, IDXX: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, SOFIVA GENOMICS Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SOFIVA GENOMICS Co Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, SOFIVA GENOMICS Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where SOFIVA GENOMICS Co's Cyclically Adjusted PS Ratio falls into.


ROCO:6615
68GF Score
SOFIVA GENOMICS Co Ltd ROCO:6615
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SOFIVA GENOMICS Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, SOFIVA GENOMICS Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=4.297/330.2130*330.2130
=4.297

Current CPI (Mar. 2026) = 330.2130.

SOFIVA GENOMICS Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 7.053 241.018 9.663
201609 6.856 241.428 9.377
201612 5.094 241.432 6.967
201703 5.142 243.801 6.965
201706 5.633 244.955 7.594
201709 5.633 246.819 7.536
201712 5.831 246.524 7.810
201803 5.374 249.554 7.111
201806 5.433 251.989 7.120
201809 5.320 252.439 6.959
201812 5.489 251.233 7.215
201903 5.699 254.202 7.403
201906 6.178 256.143 7.965
201909 6.120 256.759 7.871
201912 5.760 256.974 7.402
202003 5.565 258.115 7.119
202006 5.714 257.797 7.319
202009 5.676 260.280 7.201
202012 5.771 260.474 7.316
202103 5.832 264.877 7.271
202106 6.225 271.696 7.566
202109 5.828 274.310 7.016
202112 5.872 278.802 6.955
202203 5.880 287.504 6.753
202206 6.132 296.311 6.834
202209 5.652 296.808 6.288
202212 5.630 296.797 6.264
202303 5.288 301.836 5.785
202306 5.580 305.109 6.039
202309 5.606 307.789 6.014
202312 5.372 306.746 5.783
202403 5.664 312.332 5.988
202406 5.646 314.175 5.934
202409 4.868 315.301 5.098
202412 4.789 315.605 5.011
202503 4.437 319.799 4.581
202506 4.911 322.561 5.028
202509 3.989 324.800 4.055
202512 4.432 324.054 4.516
202603 4.297 330.213 4.297

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$26.70 mean?
SOFIVA GENOMICS Co (ROCO:6615) has a Cyclically Adjusted Revenue per Share of NT$26.70 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on SOFIVA GENOMICS Co and its competitors.
Is SOFIVA GENOMICS Co's Cyclically Adjusted Revenue per Share too high?
SOFIVA GENOMICS Co's current Cyclically Adjusted Revenue per Share is NT$26.70. Overall, SOFIVA GENOMICS Co has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does SOFIVA GENOMICS Co's Cyclically Adjusted Revenue per Share compare to TMO and DHR?
SOFIVA GENOMICS Co's Cyclically Adjusted Revenue per Share of NT$26.70 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on SOFIVA GENOMICS Co and its competitors. SOFIVA GENOMICS Co's current Cyclically Adjusted Revenue per Share is NT$26.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SOFIVA GENOMICS Co stock overvalued right now?
Based on GuruFocus' analysis, SOFIVA GENOMICS Co (ROCO:6615) is currently considered Fairly Valued. The stock's GF Value™ is NT$31.65, compared to a current price of NT$34.00 — trading 7.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$26.70. SOFIVA GENOMICS Co's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For SOFIVA GENOMICS Co (ROCO:6615), the current Cyclically Adjusted Revenue per Share is NT$26.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SOFIVA GENOMICS Co (ROCO:6615) Overvalued in 2026?

Based on GuruFocus' analysis, SOFIVA GENOMICS Co stock appears to be overvalued. The current stock price of NT$34.00 is trading 7.4% above its estimated GF Value™ of NT$31.65. GuruFocus considers SOFIVA GENOMICS Co to be Fairly Valued.

Key valuation signals for ROCO:6615:

  • Cyclically Adjusted Revenue per Share: NT$26.70
  • GF Value™: NT$31.65 vs. price of NT$34.00 (7.4% above fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6615 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


SOFIVA GENOMICS Co Business Description

Address No. 66-1, Section 1, Chongqing S. Road, 4th Floor, Zhongzheng District, Taipei, TWN, 10043
SOFIVA GENOMICS Co Ltd provides medical diagnostic services. The services offered by the company include Prenatal, Reproductive, Cancer, Precision Medicine, Newborn, and Rare Diseases. Its testing categories include Genetic, Biochemical, and Chromosome. The business items of Sofiva Group are pre-pregnancy, prenatal, and neonatal genetic testing and medical testing, and other service income. Geographically, it generates the vast majority of its revenue from Taiwan.
68GF Score

Get the complete analysis for ROCO:6615

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$34.00
Price
NT$31.65
GF Value